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Abstract: As the incidence of diabetes continues to increase in the western world, the prevalence
of chronic wounds related to this condition continues to be a major focus of wound care research.
Additionally, over 50% of chronic wounds exhibit signs and symptoms that are consistent with
localized bacterial biofilms underlying severe infections that contribute to tissue destruction, delayed
wound-healing and other serious complications. Most current biomedical approaches for advanced
wound care aim at providing antimicrobial protection to the open wound together with a matrix
scaffold (often collagen-based) to boost reestablishment of the skin tissue. Therefore, the present
review is focused on the efforts that have been made over the past years to find peptides possessing
wound-healing properties, towards the development of new and effective wound care treatments for
diabetic foot ulcers and other skin and soft tissue infections.
Keywords: antimicrobial; chronic infection; diabetes; peptides; ulcers; wound-healing; skin and soft
tissue infections (SSTI)
1. Introduction
In 2015, 8.8% of the adult population worldwide is estimated to have diabetes. This figure is
projected to rise to 10.4% by the year 2040, which underpins an alarming public health problem
that needs urgent control [1]. Diabetes is a chronic disease that stems from pancreas dysfunction,
impairing normal production of insulin which leads to high, and also fluctuating, blood glucose
levels. This, in turn, leads to an imbalance in the homeostatic regulation of the body, causing serious
health problems such as blindness, kidney failure, heart disease, venous insufficiency and peripheral
neuropathy [1]. A combination of these latter two conditions with improper footwear leads to loss of
sensitivity in the feet of diabetic patients, which facilitates installment of chronically-infected lesions,
the so-called diabetic foot ulcers (DFU), ultimately leading to limb amputations [1,2]. According to a
2012 report from the European Wound Management Agency, about 2% of the population in developed
countries suffers from non-healing injuries like DFU, and it is estimated that 25–50% of hospital
beds are occupied by patients with such an acute wound. DFU are the most common reason for
hospitalization of people with diabetes, and about one in every six people with diabetes develops at
least one foot ulcer during their lifetime. Moreover, 40–70% of all lower extremity amputations are
related to diabetes, of which 85% are preceded by DFU [3]. In addition, the quite recent “EpiCast
report: Diabetic Foot Ulcers-Epidemiology Forecast to 2025”—based on data from seven countries,
namely US, France, Germany, Italy, Spain, UK and Japan—points to over 1 million cases in 2015 and
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an estimated increase rate of 4.03% per year, which will expectedly lead to approximately 1.5 million
cases by 2025 [4].
Management of DFU should always start with prevention, through policies for foot inspection
and use of custom therapeutic footwear to prevent ulceration, as DFU are tremendously difficult to heal
once installed [3,5]. The wound-healing process comprises complex biological mechanisms triggered
by the injury, involving four key steps: (i) hemostasis; (ii) inflammation; (iii) proliferation and (iv)
tissue remodeling (Figure 1). In each of these processes, several cellular and biophysical events occur,
such as monocyte differentiation to macrophage, neutrophil infiltration and lymphocyte infiltration,
in the inflammation stage; or increased angiogenesis and re-epithelialization by fibroblast migration,
during the proliferation phase. These events may be impaired by different factors, which can be
divided into local and systemic ones. As a local factor, we can take the example of wound oxygenation,
which influences healing. In what concerns systemic factors, we can take the example of a diabetic
patient and respective individual characteristics: age, nutrition or other diseases (e.g., fibrosis, uremia),
which may give rise to problems that impair healing, such as hypoxia, dysfunction in fibroblasts and
epidermal cells, or incorrect angiogenesis, among others [6].
Management of DFU requires good knowledge of their complexity for a correct classification of
stage and severity; for instance, it is important to distinguish sloughy and necrotic tissues (severe
infection) from granulation and epithelializing ones (healing wound). Treatment of severe DFU usually
requires initial debridement to remove sloughy and necrotic tissue, followed by the use of scaffolds to
support skin rebuilding, along with efficient antimicrobial protection through a combination of several
topical agents [7,8]. Collagen-based wound dressings have been used as healing scaffolds in both skin
burns and DFU with overall promising results [9]. Those are based on animal collagens (bovine, porcine,
equine), acting as biocompatible wound/environment barriers, rather than replacing or promoting
formation of endogenous (human) collagen. While efficient production of either recombinant human
collagen or “perfect” collagen-like peptides remains an unmet goal [10], an alternative sensible option
may be the design of formulations comprising collagen-boosting instead of collagen-like components.
Actually, collagen-boosting peptides, e.g., Matrikines® like KTTKS, are already used in cosmetics to
promote extracellular matrix (ECM) production, rebuilding structure and restoring all functions of
healthy skin [11,12]. Moreover, many antimicrobial peptides (AMP) can also act as wound-healing
peptides (WHP), thus displaying the dual antimicrobial and tissue-regenerating properties highly
desired in novel topical formulations for treatment of DFU [13,14].
Today, the therapeutic value of AMP against infectious pathogens, including antibiotic-resistant
strains, is well recognized [15,16], and topical formulations of AMP have reached either the market, like
polmyxins or gramicidins, or clinical trials, such as Pexiganan (Locilex®), Lytixar, OP-145 or Novexatin,
for cutaneous, ocular and otorhinolaryngological infections [17,18]. Understandably, the literature is
quite rich in both original reports and comprehensive reviews on AMP of either natural or synthetic
origin, addressing all relevant aspects in the topic, from discovery or design to spectrum of activity,
mechanisms of action, patents, and clinical applications [15–22]. In contrast, literature focusing on the
wound-healing properties exhibited by some peptides is still emergent. As such, and considering the
undeniable timeliness of the topic, this review is focused on peptides whose wound-healing effects
may find application in the topical treatment of DFU and other skin and soft tissue infections (SSTI).
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Figure 1. Schematic overview of major stages of wound-healing. Most wound-healing peptides were found to act on one or more biochemical pathways of the 
proliferation stage, although a few have been reported to act either on earlier stages (e.g., thrombin-related peptides) or on multiple stages (e.g., Tiger17)–see text. 
Examples of wound-healing antimicrobial peptides (Table 1) in dark red, and of wound-healing non-antimicrobial peptides (Table 2) in dark blue; SAP: self-
assembling peptides (green).
Figure 1. Schematic overview of major stages of wound-healing. Most wound-healing peptides were found to act on one or more biochemical pathways of the
proliferation stage, although a few have been reported to act either on earlier stages (e.g., thrombin-related peptides) or on multiple stages (e.g., Tiger17)–see text.
Examples of wound-healing antimicrobial peptides (Table 1) in dark red, and of wound-healing non-antimicrobial peptides (Table 2) in dark blue; SAP: self-assembling
peptides (green).
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2. Wound-Healing Antimicrobial Peptides
Commonly, non-healing wounds are simultaneously colonized by different bacteria; bacterial
species most frequently isolated from such wounds typically include Staphylococcus aureus (93.5%),
Enterococcus faecalis (71.1%) and Pseudomonas aeruginosa (52.2%), among others [23]. In healthy
individuals, the innate immune system produces gene-encoded AMP that control proliferation of
pathogenic microorganisms on skin, while triggering a signaling cascade in response to injuries [24].
However, due to their typical venous insufficiency and other diabetes-related conditions, diabetic
patients are not immunocompetent, which favors formation of bacterial biofilms that are highly
refractive to current antibiotics [25]. Topical application of AMP on the infected injury may overcome
this barrier, as AMP have shown the ability to: (i) prevent infection due to their antimicrobial activity;
(ii) reduce the pro-inflammatory response; (iii) promote cell migration and proliferation [14]. As such,
many known AMP have been reported to also display wound-healing properties; some of which are
addressed in this section and compiled in Table 1.
Table 1. Examples of peptides with dual antimicrobial and wound-healing properties. Peptide
sequences are displayed using the one-letter amino acid code, as per the IUPAC-IUBMB Joint
Commission on Biochemical Nomenclature rules.
Peptide Name Peptide Sequence Reference
AG30 MLSLIFLHRLKSMRKRLDRKLRLWHRKNYP
[26]
AG30/5C MLKLIFLHRLKRMRKRLKRKLRLWHRKRYK
AH90 ATAWDFGPHGLLPIRPIRIRPLCG [27]
CW49 APFRMGICTTN [28]
Cys-KR12 KRIVKRIKKWLR [29]
Esculentin-1a(1-21) GIFSKLAGKKIKNLLISGLKG [30]
hBD-1 DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK(Disulfide bridges: 5-34, 12-27, 17-35)
[31,32]
hBD-2 GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP(Disulfide bridges: 8-37, 15-30, 20-38)
hBD-3 GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK(Disulfide bridges: 11-40, 18-33, 23-41)
hBD-4 ELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRK(Disulfide bridges: 6-33; 13-27; 17-34)
Histatin-1 DSHEKRHHGYRRKFHEKHHSHREFPFYGDYGSNYLYDN
[33]Histatin-2 RKFHEKHHSHREFPFYGDYGSNYLYDN
Histain-3 DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN
IDR-1018 VRLIVAVRIWRR [34]
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES [35]
MSI-78 (pexiganan) GIGKFLKKAKKFGKAFVKILKK [36]
Pep19-2.5 GCKKYRRFRWKFKGKFWFWG [37]
PLL-37 PLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES [38]
SHAP1 APKAMKLLKKLLKLQKKGI [39]
SR-0007 MLKLIFLHRLKRMRKRLKRK
[40]
SR-0379 MLKLIFLHRLKRMRKRLkRK 1
Temporin A FLPLIGRVLSGIL
[41]
Temporin B LLPIVGNLLKSLL
1 Lowercase letters indicate D-amino acid residues; Peptide highlighted in bold was entered into clinical trials for its
assessment in the treatment of diabetic foot ulcers; S: phosphoserine.
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2.1. Human-Based Defence Peptides
Human genetically-encoded AMP that are expressed on skin, among other tissues, as part of the
body’s immune response to injury include the well-known human β-defensins (hBDs) [31], cathelicidin
LL-37 [35] and dermcidins [42]. One of the endogenous AMP that gained more attention in the context
of DFU healing was human cathelicidin LL-37. In 2008, Carretero et al. reported that in vivo adenoviral
transfer of LL-37 AMP to excisional wounds in diabetic-ob/ob mice (mutant obese mice used as animal
models of type II diabetes), improved re-epithelialization and granulation tissue formation [43].
This was later confirmed by Ramos et al., who tested both LL-37 and PLL-37 (LL-37 derivative with
an N-terminal proline) in vitro and in vivo skin lesions with impaired wound-healing, as they found
both peptides to promote re-epithelialization and angiogenesis [38]. Shortly after, in 2012, LL-37 was
compared to another AMP, the innate defense regulator peptide 1018 (IDR-1018) [34]. The study
revealed that IDR-1018 was less toxic than LL-37 in vitro, and demonstrated significantly accelerated
wound-healing in S. aureus-infected porcine and non-diabetic murine wounds. However, the study
showed that IDR-1018 neither accelerated healing nor differed significantly from LL-37 with regards to
bacterial colonization of DFU in diabetic mice. Moreover, diabetes seemed to have a negative impact
on mice immune responses, eventually blocking signaling pathways where innate defense regulators
like LL-37 and IDR-1018 are involved [34].
Also in 2012, Rivas-Santiago et al. used primary cell cultures from DFU to study the expression
and role of human endogenous AMP, including LL-37 and β-defensins hBD-1, hBD-2, hBD-3 and hBD-4,
in wound-healing [32]. These authors found that although β-defensins are expressed in DFU, their
production seems to be not high enough to contain infection and promote proper wound-healing.
The study also showed that when compared with healthy skin, DFU biopsies presented low or
null levels of LL-37, which might contribute to DFU pathogenesis. Moreover, topically-applied
exogenous LL-37, i.e., peptide added to the wound site, was degraded by proteases presented in
the wound [32]. These observations were later confirmed by McCrudden et al., who found that
topically-administered LL-37 was unstable in the microenvironment of DFU, probably by the action
of both host and bacterial proteinases that cleaved LL-37 into smaller peptides [44]. The authors
thus suggested that to overcome the degradation process, LL-37 analogues should be developed
to include some simple structural modifications, e.g., the replacement of α- by β-amino acids [44].
While investigating how to increase concentration of endogenous LL-37 at wound sites, Gonzalez-Curiel
et al. found that the addition of 1,25-dihydroxyvitamin D3 and L-isoleucine to the wound increased
production of hBD-2 and LL-37 during the regeneration process in primary cultures of cells from DFU
sites [45]. All these promising findings on the wound-healing potential of LL-37 have culminated with
this peptide entering clinical trials for venous leg ulcer treatment in 2014; results thereof suggested
that LL-37 is safe and has a significant dose-response activity, although in no case could total wound
closure be observed, which was attributed to the short trial period [46]. More recently, Song et al.
immobilized an LL-37 derivative, Cys-KR12, onto electrospun silk fibroin (SF) nanofiber membranes [29].
Cys-KR12 includes residues 18–29 of the LL-37 sequence, and was chosen due to its antimicrobial and
anti-biofilm action against four different bacterial strains (S. aureus, S. epidermidis, E. coli and P. aeruginosa).
The peptide-modified membranes were found to promote proliferation of keratinocytes, fibroblasts and
monocytes, all important players in the wound-healing process [29]. Taken together, results gathered
thus far on the potential of LL-37 towards the healing of DFU and other SSTI are quite promising,
regarding the use of LL-37 both for adequate formulation as a topical antimicrobial agent and for the
coating of biomedical materials amenable to being applied as wound dressings.
At the same time as LL-37 was gaining more attention in the context of DFU healing, Nishikawa and
co-workers developed an antimicrobial helical peptide—AG-30 (Table 1)—with angiogenic properties
potentially similar to those of LL-37 [47]. However, since peptides are typically unstable in vivo,
they engaged in the synthesis of AG30-related peptides as leads for clinical applications [26]. In this
context, and in order to stabilize the AG-30 helical structure, the design strategy consisted of replacing
several neutral residues (specifically proline, asparagine and serine) with cationic or hydrophobic
Molecules 2017, 22, 1743 6 of 18
amino acids [26]. As a result, AG30/5C (Table 1), where five residues of the original sequence AG30
were replaced by cationic amino acids, displayed improved antimicrobial and angiogenic activities
when tested in vivo in a diabetic mouse wound-healing model with methicillin-resistant S. aureus
(MRSA) infection [26]. By further evaluating the metabolic stability of AG30/5C, Tomioka et al. found
that SR-0007 (Table 1), a 20-residue metabolite, stimulated cell proliferation at levels similar to those
of the parent peptide [40]. However, as SR-0007 was rapidly degraded by human serum at 37 ◦C,
a native L-lysine residue was replaced by its D enantiomer, yielding an analogue (SR-0379, Table 1)
with significantly improved stability [40]. This peptide displayed antimicrobial activity against several
distinct bacteria, including drug-resistant strains, and significantly accelerated wound-healing on a
full-thickness wound model with a skin flap in a streptozotocin-induced diabetic rat model, holding
great promise in the treatment of MRSA-positive diabetic ulcers [40].
Motivated by the fact that wounds in the oral cavity heal much faster than skin lesions, Oudhoff and
co-workers engaged in a study to assess the factors in human saliva that contribute to its wound-healing
properties [33]. By testing saliva and saliva protein fractions in an in vitro model for wound closure
using an epithelial cell line, these researchers identified histatin-1 (Hst1), histatin-2 (Hst2) and histatin-3
(Hst3) (Table 1), rather than epidermal growth factor as primarily thought, as the major wound-healing
factors in human saliva [33]. This finding was quite surprising because salivary histatins had, up to
then, only been implicated in the antifungal saliva weaponry. Still, Oudhoff et al. found that the
two activities—cell-stimulating and antimicrobial—are very distinct in their mode of action as the
latter is independent of the chirality of the peptide and occurs via disruption of the phospholipid
membrane of the target cell [33]. On the contrary, the stimulating activity on host cells involves a
stereospecific interaction with a putative membrane receptor [33]. To ascertain whether histatins have
potential applicability as general wound-healing agents, Oudhoff et al. further tested those peptides in a
tissue-engineered epidermal skin that closely resembled native healthy skin [48]; the study showed that
histatins enhance re-epithelialization by stimulating cell spreading and migration, but do not increase
cell proliferation [48]. Additionally, by comparing the wound-healing activities of Hst1 fragments
that differ by 2-residue-stepwise truncation in the N- or C-terminus, or both, they found that the
region comprising residues 20 to 32 (SHREFPFYGDYGS) is critical for peptide biological activity [48].
Interestingly, they have also shown that constraining the conformation of Hst1 by cyclization resulted in
a 1000-fold increase of its wound-healing activity in the in vitro wound-scratch assay [48]. These results
have clearly established synthetic histatins as potential candidates for novel topical medicines to treat
skin lesions, namely chronic ones. However, peptide-based therapeutics for wound-healing stimulation
are sensitive to several proteases present in the chronic wound bed. Therefore, Boink et al. tested the
in vitro stability of some histatin variants (Hst1, Hst2, cyclic Hst1 and minimal active domain of Hst1) in
diluted chronic wound extracts, in order to determine if those peptides would remain stable in chronic
ulcers long enough to exert their migration-stimulating activity [49]. The results showed a breakdown
of ca. 50% for Hst1 and Hst2, and of ca. 20% for the minimal active domain of Hst1 and cyclic Hst1, in
8 h. As such, Boink et al. suggested that further investigations on the potential of the latter two Hst1
derivatives as topical therapeutics for SSTI should be undertaken [49].
2.2. Amphibian-Based Defence Peptides
Pexiganan, also known as MSI-78, is another AMP whose therapeutic potential against DFU
has been widely recognized; it is a 22-residue linear cationic AMP analogue to magainins, which are
natural AMP isolated from the skin of the African clawed frog Xenopus laevis [50]. By the turn of the
century, 1% pexiganan acetate cream was proposed for topical treatment of mild to moderate DFU,
as an alternative to the classical ofloxacin-based oral antibiotherapy [36]. Indeed, in the course of earlier
clinical trials where patients were treated either with pexiganan cream or with active oral antibiotics,
and compared with the placebo group, pexiganan’s performance proved it to be a possible alternative to
oral antibiotics [51]. These findings triggered several research works focused on pexiganan and related
peptides [52–54], and motivated the patenting of a 0.8% pexiganan acetate cream (Locilex®, earlier
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known as Cytolex) in several countries, by the pharmaceutical company Dipexium Pharmaceuticals, Inc.
(Houston, TX, USA) in 2016 [55,56]. However, Locilex® failed approval by the competent international
organizations, on the grounds that its efficacy was not proven superior to that of classic oral antibiotics
in any of the clinical trials undertaken to date, which include a recent Phase 3 clinical trial promoted
by Dipexium, now merged with PLx Pharma, Inc. (Houston, TX, USA) [57]. Remarkably, AMP such
as magainins and related peptides, like pexiganan, are not the only wound-healing peptides found,
or inspired, in secretions from the skin of amphibians including frogs, toads and salamanders [58,59].
In fact, many known AMP are of amphibian origin, and most of them have revealed wound-healing
properties, possibly contributing to the fast wound re-epithelialization typical in many species of the
Amphibia class: e.g., the process takes less than 10 h in salamanders, while needing two to three days in
mammalians. In agreement with this assumption, Liu et al. were able to isolate a new short (11 residues)
AMP from the skin of Odorrana grahami frogs, CW49 (Table 1), which was found to promote angiogenesis
while preventing excessive anti-inflammatory response when tested in DFU [14,28]. Interestingly,
the same authors isolated another wound-healing AMP, peptide AH90 (Table 1), from the skin of
the same frog species, and found it to have wound-healing activity, although this was not tested in
DFU [27].
In addition to the above, there is a large collection of AMP of diverse origin whose healing ability
has been demonstrated on SSTI other than DFU. Regardless of having been tested in DFU or not,
any wound-healing AMP encloses the potential to become a useful topical agent against this particular
type of SSTI. In this connection, one such recent example is the work performed by Di Grazia and
co-workers, who have reported that temporins A and B (Table 1), two short AMP isolated from the
skin of the European red frog Rana temporaria, promote in vitro wound-healing in a monolayer of
immortalized human keratinocytes (HaCaT cells) [41]. Moreover, they have also found that both
temporins, although to different extents, can reduce the number of S. aureus bacteria inside HaCaT
keratinocytes in a dose-dependent manner. Temporin B, the most active of both peptides, kills ca. 80%
of the bacterial cells at its highest non-cytotoxic dosage (16 µM) within 2 h [41]. These results suggested
that temporins are attractive candidates for the generation of new therapeutics to treat S. aureus-related
SSTI. The same researchers further reported that esculentin-1a(1-21) (Table 1), a derivative of AMP
esculentin-1a isolated from the skin of the frog Rana esculenta, significantly stimulates migration of
HaCat cells over a wide range of peptide concentrations (0.025–4 µM), being notably more efficient
than LL-37 [30]. This observation, allied with the established antimicrobial activity for the same
esculentin-1a derivative, namely its high anti-Pseudomonal activity, makes this AMP a promising
wound-healing promoter, especially against chronic, often Pseudomonas-infected, skin ulcers [30].
2.3. Synthetic Peptides
Synthetic AMP, designed for improved structural stability and high antimicrobial activity under
physiological conditions, have been found to also present wound-healing activity [37,39]. One example
was reported in 2014 by Kim et al., who demonstrated that SHAP1 (Table 1), a synthetic AMP
with potent antimicrobial activity against fungi and bacteria in the presence of 200 mM NaCl,
also produces wound closure both in vitro and in vivo [39]. Indeed, SHAP1 displayed stronger
in vitro wound-healing activity than LL-37 by inducing HaCaT cell migration, which was reported to
occur via transactivation of the epidermal growth factor receptor [39]. One important finding was that
topical application of SHAP1 accelerated closure and healing of full-thickness excisional wounds in
mice at the same low concentration (1 µM) that was used in in vitro assays [39], indicating that SHAP1
stands as a highly promising topical agent for treatment of SSTI.
In 2016, Pfalzgraff et al. also assessed the potential of Pep19-2.5 (Table 1), a synthetic
anti-lipopolysaccharide peptide presenting antimicrobial activity for Gram-negative and Gram-positive
bacteria, for therapeutic applications in bacterial skin infections [37]. The results showed that Pep19-2.5
displays low in vitro cytotoxicity in primary human keratinocytes and fibroblasts. Furthermore,
it reduces the immune and inflammatory responses in skin cells stimulated with potent bacterial
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pathogenicity factors, with concurrent potent stimulation of keratinocyte migration; this suggests that
Pep19-2.5 might be a promising option for the treatment of acute and chronic wounds most commonly
infected with S. aureus and P. aeruginosa [37].
An interesting and very recent example of a highly promising synthetic wound-healing AMP
is that of DRGN-1, developed by Chung et al. who sought inspiration in a histone H1-derived
peptide from the Komodo dragon (Varanus komodoensis) [60]. DRGN-1 was found to display potent
antimicrobial and anti-biofilm activity, and to permeabilise bacterial membranes, while being equally
able to promote significant tissue regeneration ability in vitro; according to the authors, based on
data from scratch wound closure assays, the wound-healing ability of DRGN-1 is due to promotion
of migration of HEKa keratinocytes and activation of the EGFRSTAT1/3 pathway. The potential
of DRGN-1 as a wound-healing agent was further confirmed in vivo, as the peptide was able
to significantly enhance wound-healing in both uninfected and mixed biofilm (P. aeruginosa and
S. aureus)-infected murine wounds [60].
3. Tissue Regeneration Peptides
As seen in the previous section, some AMP are considered promising agents for wound care
because, in addition to their intrinsic antimicrobial activity, they can influence different mechanisms
of the wound-healing orchestration such as inflammation, epithelialization, tissue granulation and
remodeling. Still, although some wound-healing peptides do not display antimicrobial properties,
some of them have great therapeutic potential towards healing chronically-infected wounds, like DFU
and other SSTI. Recent examples of such peptides are summarized in Table 2 and next reviewed.
Table 2. Examples of non-antimicrobial peptides presenting wound-healing activity. Peptide sequences
are displayed using the one-letter amino acid code, as per the IUPAC-IUBMB Joint Commission on
Biochemical Nomenclature rules.
Peptide Name Peptide Sequence Reference
Ac-PGP N-acetylated-PGP [61]
BioGHK Biotinylated-GHK [62]
Col4-1 MFRKPIPSTVKA
[63]Comb1 DINECEIGAPAGEETEVTVEGLEPG
E1 GETGPAGPAGPIGPVGARGPAGPQGPRGDKGETGEQ [64]
Tiger17 WCKPKPKPRCH [65]
TP-508 AGYKPDEGKRGDACEGDSGGPFV [66]
TSN1 NFQGVQNRFVFGTP
[67]
TSN2 MENAELDVPIQSVFTR
TSN3 NTDNIYPESSC
TSN4 PYLGYVFK
TSN5 MQTVAQLFKTVSSLSLST
TSN6 HSPDIQLQKGLTFEPIQIK
TSN7 STITQPYKTLNNARSP
TSN8 RPGPSPEGTGQSYNY
TSN9 MENAELDPPYLGYVFK
TSN10 TGQSYNQYSQRPYLGVYVFK
TSN11 LYGQTPLETL
TSN12 ELADSPALEIG
TSN13 LYGQTPLETLELADSPALEIG
TSN14 VSGNTVEYALPTLE
TSN15 LDSPTAPTVQSTALTWRP
TSN16 LDGSAPGPLYTGSALDF
TSN17 GSEGVRSGRSG
TSN18 QPQPLPSPGVGGKN
Tylotoin KCVRQNNKRVCK [59]
UN1 ELLESYIDGR
[68]UN2 TATSEYQTFFNPR
UN3 ELLESYIDGRPTATSEYQTFFNPR
WKYMVm WKYMVm 1 [69]
1 Lowercase letters indicate D-amino acid residues; Peptide highlighted in bold was entered into clinical trials for its
assessment in the treatment of diabetic foot ulcers.
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3.1. Human-Based Peptides
One class of non-antimicrobial peptides that promote tissue repair is that of thrombins.
Thrombins and related peptides are known for their important role in blood clotting, whereby they
promote cleavage of soluble fibrinogen into fibrins. TP-508 (Table 2) is a peptide fragment of the
receptor-binding domain of native human thrombin, whose saline solutions, also known as Chrysalin®,
have been tested for DFU healing. In the course of phase I and phase II clinical trials, Chrysalin®
showed 45–72% of complete healing compared with the placebo group, without relevant local wound
reactions or observable adverse effects [66].
In 2011, Demidova-Rice et al. reported that several bioactive peptides, liberated from capillary
endothelial cells degradation by Clostridium histolyticum collagenase, facilitate endothelial responses to
injury and angiogenesis [63]. Two peptides in particular, Col4-1 and Comb1 (Table 2), when used at
10–100 nM, were found to increase rates of microvascular endothelial cell proliferation by up to 47% and
in vitro angiogenesis by 200% when compared with serum-stimulated controls [63]. These researchers
later assessed whether these peptides could improve wound-healing in vivo, and found that Comb1,
when applied into impaired cranial dermal wounds created in cyclophosphamide-treated mice, could
stimulate the rate of wound closure [68]. Moreover, they identified three novel peptides derived
from human platelet-rich plasma, UN1-UN3 (Table 2), which stimulate epithelial migration as well as
angiogenesis in vitro [68]. Yet, UN3 was shown as the most potent stimulator of cellular responses,
by causing a 250% increase in angiogenic response, a 50% increase in endothelial proliferation and a
tripling of epithelial cell migration in response to injury [68]. Additionally, results of in vivo experiments
where UN3 and Comb1 were added together to impaired cranial wounds in cyclophosphamide-treated
mice showed an increase of the number of blood vessels present in the wound beds. Interestingly,
combining the peptides before addition to the cells in vitro did not produce any synergistic effects [68].
Motivated by these promising findings, the same authors further investigated whether Comb1 and UN3
could stimulate healing in a diabetic porcine model highly reminiscent of human healing impairments in
type-I and -II diabetes [70]. This study revealed that both peptides significantly improve angiogenesis and
re-epithelialization in diabetic porcine wounds when compared to saline-treated controls. Although the
authors found that both peptides stimulate wound closure through upregulation of cytokines and
multiple reparative growth factors, their precise mechanism of action remains unclear [70]. At the
same time, this same research group postulated that Santyl®, a FDA approved debridement agent
containing Clostridial collagenases and other non-specific proteases, could also provide healing through
the production of bioactive peptides able to stimulate tissue and cellular responses to injury [67].
Indeed, they were able to identify several bioactive peptides (TSN1-8, TSN11-12, TSN14-17; Table 2)
when doses of Santyl® collagenase, comparable to those used clinically, were applied to human
dermally-derived capillary ECM [67]. Interestingly, there is little overlap between these peptides,
arising from Santyl® collagenase, and the endothelial peptides (Comb1 and UN3) produced by
purified Clostridial collagenase. The authors next found that the individual peptides released from
Santyl®-digested ECM, as well as the combinatorial peptides (TSN9-10, TSN13 and TSN18; Table 2)
induced wound-healing in vitro, highlighting TSN6 and TSN18 as those having the greatest stimulatory
activity over all cell types and parameters assayed [67]. When they further applied these peptides to
healing-impaired cyclophosphamide-treated mice, they observed that 0.1 mg/mL TSN18 stimulated
a >100% increase of epithelial responses, while 1.0 mg/mL TSN18 produced a 60% increase in
epithelialization when compared to controls [67]. Overall, these results indicate TSN18 as an exciting new
opportunity for creating advanced wound-healing therapies. In parallel to the aforementioned studies,
the therapeutic effect of WKYMVm (Table 2)—a short synthetic agonist of formyl peptide receptor 2
known to promote angiogenesis—on DFU was investigated by Kwon and co-workers [69]. As such,
this peptide was tested in cutaneous wounds of streptozotocin-induced diabetic rats, where it was
found to accelerate angiogenesis, granulation tissue formation, re-epithelialization and wound closure,
suggesting its potential usefulness to treat chronic cutaneous wounds [69].
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Findings like the above motivated other approaches to non-antimicrobial wound-healing peptides
that sought inspiration on platelet-rich plasma and ECM proteins. This gave rise to new classes of
wound-healing peptides, such as the so-called matrikines, matricryptins, and laminin analogues,
among others. Matrikines, i.e., ECM-inspired peptides, have been described to promote collagen
formation in fibroblasts, leading to skin repair, but their therapeutic potential has also been surveyed
for cancer, inflammation and neurodegenerative disorders, as well as for cosmetic applications [12,71].
A typical matrikine is tripeptide GHK (Figure 2), well known for its ability to form copper(II) complexes,
anti-inflammatory and wound-healing properties, as well as for its capacity to improve skin density
and firmness [62]. In 2005, Arul et al. reported that a biotinylated GHK derivative (BioGHK, Figure 2)
incorporated in a collagen matrix showed better wound-healing in vivo than the collagen matrix
alone [72].
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Later on, the same group tested the same system in skin wounds of diabetic rats, and were able
to observe an increase in collagen biosynthesis, along with activation and growth of fibroblasts [73].
This result is rather encouraging regarding the potential of matrikines for topical treatment of
DFU and other SSTI. A very recent example of the tremendous potential of matrikines regards
the work from Banerjee and co-workers, who have investigated the wound-healing ability of E1
(Table 2), a cryptic peptide derived from bovine Achilles tendon collagen [64]. The results showed
that topical administration of E1 at a concentration of 60 µM greatly increased wound closure
throughout the duration of the experiment, while >90% tissue restoration was observed on the 12th day,
when compared to 55% restoration for the control group [64]. Similarly, Kwon and co-workers have
explored the effects of Ac-PGP (Table 2), a peptide derived from degradation of collagen, on cutaneous
wound-healing and neovascularization in human endothelial progenitor cells (hEPCs) [61]: following
enhanced proliferation, migration and tube-forming activity of hEPCs upon in vitro treatment with
Ac-PGP, in vivo assays further demonstrated that topical application of this peptide accelerates wound
closure by 11 to 23% with promotion of neovascularization, in comparison with the control group [61].
These results suggested that Ac-PGP should be pursued as a potential therapeutic product for treatment
of chronic and acute wounds.
3.2. Amphibian-Based Peptides
As mentioned in the previous section, several AMP of diverse origin, namely those isolated from
amphibians, have demonstrated healing properties on different wound types in addition to their
intrinsic antimicrobial activity. Interestingly, some peptides derived from such A P were found to
lose their antimicrobial ability, while retaining strong wound-healing activity. One such example is
that of tylotoin (Table 2), a short peptide derived from the C-terminus of a cathelicidin extracted from
the skin of the Tylototriton verrucosus salamander [59]. Mu et al. found that, although tylotoin did
not show any antimicrobial activity, it significantly improved in vitro proliferation and migration of
vascular endothelial cells, fibroblasts and keratinocytes [59]. In vivo assays further demonstrated the
Molecules 2017, 22, 1743 11 of 18
wound-healing ability of tylotoin as its topical application markedly enhanced wound-healing in a
mouse model of full-thickness skin wounding. The same work further revealed that tylotoin also
promotes the release of transforming growth factor β1 and interleukin 6, which are essential in the
wound-healing process, thus suggesting tylotoin as a valuable template for development of novel
wound-healing agents [59]. Similarly, Tang and co-workers have reported Tiger17 (Table 2), a cyclic
peptide derived from the AMP tigerinin isolated from skin secretions of the Fejervarya cancrivora
frog, as a non-AMP with excellent skin wound-healing ability [65]. These authors found that topical
application of Tiger17 greatly diminished wound closure time in a full-thickness skin wound mouse
model, and that the peptide was involved in three stages of wound-healing: (i) the inflammatory
stage, by recruiting macrophages to the wound site; (ii) re-epithelialization and granulation tissue
formation, by promoting proliferation and migration of both keratinocytes and fibroblasts; and (iii) the
tissue remodeling phase, by activating mitogen-activated protein kinases signaling pathways and by
stimulating the release of interleukin 6 and transforming growth factor β1 in murine macrophages [65].
Altogether, these results clearly indicate Tiger17 as a promising wound-healing lead.
3.3. Self-Assembling Peptides
One other quite promising class of peptides for wound-healing, given their ability to promote
tissue regeneration, is that of self-assembling peptides (SAP). Peptide amphiphiles (hybrid compounds
that comprise both an alkyl and a peptide tail) are examples of important SAP-based scaffolds for
tissue engineering [74]. By virtue of their properties, SAP and other peptides able to promote
tissue regeneration can assume an important role in wound-healing, being potentially useful for
topical treatment of DFU and other SSTI. In 2006, Ranjagam et al. developed peptide amphiphile
PA (Figure 3) [75], based on the consensus sequence XBBBXXBX (X = hydrophobic amino acid;
B = basic amino acid) earlier designed for heparin-binding [69], since heparin plays an important role
in nanostructure nucleation into macromolecules able to efficiently activate, and bind to, angiogenic
growth factors.
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Figure 3. Structure of the peptide amphiphile PA, developed by Ranjagam and co-workers [75].
The authors observed that aqueous mixtures of PA, heparin, vascular endothelial, and fibroblast
2 growth factors, were able to promote extensive blood vessel formation in vivo. Moreover, they
found a peptide sequence that self-assembled into nanofibers upon interaction with heparin [75].
Later, Mammadov et al. developed a heparin-mimetic PA (hmPA, Figure 4), designed to display
the angiogenesis-promoting properties of heparin, without the need to add this glucosaminoglycan,
or exogenous growth factors; their working hypothesis was confirmed, as hmPA was able, by itself,
to promote angiogenesis and tissue regeneration [76].
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These findings motivated Senturk et al. to test the ability of hmPA-based gels to heal diabetic
wounds, in streptozotocin-induced diabetic mice; results confirmed the bioactive gels to have a key
role in both inflammation and proliferation phases of wound-healing, by promoting angiogenesis,
re-epithelialization and inflammatory response [77].
Several wound dressings are available in the clinics for superficial treatment of mild to severe
wounds, starting from simple gauze up to highly complex materials which include films, hydrogels,
foams, hydrofibers and engineered skin substitutes [78]. Current biomedical approaches for advanced
wound care aim at providing scaffolds to support skin rebuilding, along with efficient antimicrobial
protection, given that over 50% of chronic SSTI are associated with bacterial biofilms underlying severe
infections that contribute to tissue destruction, delayed wound-healing, and other complications [8].
Under certain conditions, SAP self-assemble to produce supramolecular structures; hence, several
groups have looked into their use as appropriate scaffolds for the production of wound dressings.
This is a broad and fascinating topic that has been reviewed in great detail by others, and is therefore
outside the scope of the present review [79,80]. Still, some recent examples of peptide-based wound
dressings will be addressed next.
4. Peptide-Based Wound Dressings
Collagen-based wound dressings have been used as healing scaffolds in both skin burns and DFU
with overall promising outcomes, as collagen plays an important role in tissue regeneration, stabilizing
the vascular and cellular components in the wound [9,81]. Collagen applied in saline-moistened
gauze has been tested in DFU, with encouraging results [82]. Recently, Choudhary et al. reported the
wound-healing activity of collagen-based dressings as compared to conventional (dry) dressings;
the study included 60 diabetic patients, most of them with traumatic foot injuries followed by
installation of a diabetic ulcer, with those being treated with the collagen-based dressing showing
more pronounced regression of infection and appearance of granulation tissue [83]. Still, collagen
alone cannot provide antimicrobial protection, which motivated research initiatives where collagen
was mixed with other biocompatible biopolymers, such as chitosan, whose intrinsic antimicrobial
and wound-healing properties are very well known [84]. Other polysaccharides (e.g., dextrin and
alginate) and AMP have also been considered as relevant components to build new generation wound
dressings able to simultaneously provide (i) scaffold for skin rebuilding; (ii) tissue-regeneration;
and (iii) antimicrobial action [85,86]. In this context, Xiao et al. recently prepared a chitosan-collagen
hydrogel grafted with peptide QHREDGS, an angiopoietin-1 derivative that promotes migration of
human primary keratinocytes and activates kinase B Akt, thus being potentially useful against DFU.
The peptide-tethered hydrogel was proven to (i) protect keratinocytes against hydrogen peroxide
stress in a dose-dependent manner; (ii) promote migration of keratinocytes from both healthy and
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diabetic people; (iii) accelerate and enhance wound closure; and (iv) promote angiogenesis, as the total
number of blood vessels was greater in the peptide-hydrogel treated wounds, although no difference
was observed in vessel density or size inside the wound [87].
Cellulose and derivatives embedding wound-healing peptides have also been tested on DFU.
One recent example concerns the use of peptide ACT1 (RQPKIWFPNRRKPWKKRPRPDDLEI),
a mimetic of the C-terminus of connexin43, a protein identified as potentially useful for treatment of DFU.
ACT1 was embedded in a hydroxyethyl-cellulose hydrogel, and this formulation was topically applied
on DFU [88]. As the results demonstrated the peptide-embedded gel to expedite re-epithelization while
being non-toxic [88], a randomized phase III clinical trial was initiated in July 2015 to determine whether
this gel (Granexin) is safe and effective in the treatment of diabetic foot ulcers [89].
Whole cells have also been regarded as potentially useful “biomaterials” for topical delivery
of wound-healing peptides. Very recently, Seo et al. tested a combination of peptide exendin-4
(HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS), a glucagon-like peptide-1 receptor agonist,
with adipose tissue-derived stem cells, for healing DFU on db/db mice, which are animal models of
diabetic dyslipidemia. This combination performed significantly better than local injection of only
the stem cells, but it remains to be determined whether the effect of the combination is synergistic or
additive [90].
5. Conclusions
Wound-healing is a complex multi-stage process towards the rebuilding of skin. In many diverse
pathologies, such as diabetes mellitus, normal wound-healing is impaired, which may lead to severe
complications, from ulcers to chronic skin infections. As such, advanced biomedical approaches
for effective wound care aim at providing antimicrobial protection to the open wound together
with promotion of fast and correct healing, so that a fully functional healthy skin can be swiftly
restored. Today, the therapeutic value of AMP against infectious pathogens, including parasites, is well
recognized, and several topical formulations containing AMP are currently in clinical use. In parallel,
a plethora of wound-healing peptides and peptide-grafted dressings has been unveiled in the past
few years, holding great promise for novel strategies for treatment of chronically infected wounds.
The development of peptide-based materials for topical application in DFU and other SSTI is still in its
infancy, and its future seems quite promising and exciting: based on findings made thus far, future
joint efforts of peptide scientists and healthcare professionals working in this area will likely produce
innovative solutions to this health issue, increasingly prevalent worldwide.
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